Fusion Antibodies (LON:FAB) Shares Up 14.3% – Should You Buy?

Fusion Antibodies plc (LON:FAB)’s share price traded up 14.3% on Tuesday . The stock traded as high as GBX 8.40 ($0.11) and last traded at GBX 8.40 ($0.11). 1,025,288 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 1,646,707 shares. The stock had previously closed at GBX 7.35 ($0.09).

Fusion Antibodies Trading Down 3.5 %

The business’s 50-day simple moving average is GBX 8.10 and its 200-day simple moving average is GBX 5.44. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40. The company has a market cap of £7.49 million, a PE ratio of -1.79 and a beta of 0.49.

Fusion Antibodies (LON:FAB) last announced its quarterly earnings data on Tuesday, November 19th. The company reported GBX (0.80) (($0.01)) earnings per share (EPS) for the quarter. Fusion Antibodies had a negative return on equity of 137.11% and a negative net margin of 195.95%. As a group, analysts expect that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.